STRATEC signed an agreement to acquire the BioSciences business of Sony DADC

- Significantly expands product portfolio to include smart consumables
- Diversifies overall customer structure and extends value chain
- Complementary service portfolio adds recurring revenue stream
- Revenue expectation of around EUR 17 million for current financial year

Birkenfeld, June 8, 2016

STRATEC Biomedical AG, Birkenfeld, Germany (Frankfurt: SBS; Prime Standard, TecDAX), today signed an agreement with Sony DADC Austria AG ("Sony DADC"), based in Anif/Salzburg, Austria, to acquire all of the shares of its BioSciences business, Sony DADC BioSciences GmbH ("Sony DADC BioSciences"), which is a wholly-owned subsidiary of Sony DADC. The acquisition is expected to be completed by the end of the third quarter 2016.

Building on Sony DADC's experience in high-precision optical disc manufacturing, Sony DADC induced 6 years ago the formation of its BioSciences business. Sony DADC BioSciences is a leading global OEM supplier of smart consumables for diagnostics, life sciences and medical technology applications. The company has a unique combination of skills and technologies including nano- and microstructuring, coating technologies, polymer sciences, and automated assembly. Sony DADC BioSciences has a certified production facility and a global logistics network and covers the entire value chain, from development and design via production and quality assurance through to logistics. The company meets all regulatory requirements in the relevant target markets. Its customers include global players in highly regulated markets as well as innovative start-ups. Furthermore, the company has numerous partnerships with universities and research institutes. Alongside its headquarters in Anif near Salzburg in Austria, the company has sales offices in both Asia and America.

In the current financial year, ending on March 31, 2017, the company is expected to generate sales of around EUR 17 million with slightly positive earnings contributing to STRATECs EBIT. Based on current planning, the management teams expect a continuously growing EBIT margin to reach the current group's EBIT margin by 2020. Consolidation within the STRATEC group is expected after closing. The company currently has approximately 120 employees. The company valuation set in the sale and purchase agreement amounts over EUR 30 million.

Comments Marcus Wolfinger, CEO of STRATEC: "With the acquisition of Sony DADC BioSciences, we are expanding the STRATEC Group to include an innovation leader in a very attractive growth market. This combination of an experienced, highly qualified team with innovative products and established customer relationships is an ideal addition to STRATEC's product portfolio. After closing this acquisition we will be able to offer solutions to our customers from a significantly broader technology spectrum, one that encompasses entirely new solutions in the field of smart consumables. We have been co-operating with the team in Anif in several major development projects for several years now and are impressed by their professionalism and innovative power. We believe that pooling our strengths this way will help us to access new growth opportunities for the STRATEC Group while also diversifying cluster risks."

Dr. Chris Mauracher, Managing Director of Sony DADC BioSciences added: "The two business models are very similar in terms of their partnership-driven approach, transferring development activities into continuous cash flow generating production. Given our different positions within the same value chain, we thus complement each other ideally. This combination now enables us to offer complete solutions comprising instrumentation, consumables and smart consumables from one single source. From a customer perspective, that reduces the number of contact partners and thus the complexity and process risk. We are optimistic that this will soon also be reflected in an even better offer to order ratio with our partners."

About STRATEC
STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies.
Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the TecDAX select index of the German Stock Exchange.

About Sony DADC BioSciences GmbH
Building on Sony DADC's experience in high-precision optical disc manufacturing, Sony DADC BioSciences partners with Life Sciences and Diagnostics companies enabling the industrial manufacturing of smart polymer parts.

About Sony DADC
Sony DADC is a leading disc and digital solution provider for the entertainment, education and information industries, offering world-class optical media replication services, digital and physical supply chain solutions and software services. The company's network consists of service offices, optical media production, distribution and digital facilities worldwide.

Further information can be obtained from:
STRATEC Biomedical AG
André Loy, Corporate Communications
Gewerbestr. 37, 75217 Birkenfeld
Germany
Tel: +49 7082 7916-190
Fax: +49 7082 7916-999
ir@stratec.com
www.stratec.com

Sony DADC International
Karin Ploner, Communications
Sonystr. 20, A-5081 Anif/Salzburg
Austria
Tel: +43 6246 880 8398
karin.ploner@sonydadc.com
www.sonydadc.com